Jun. 16 at 3:16 AM
Phio Pharmaceuticals Corp. PH-762 silences PD-1 inside a tumor to help the immune system attack cancer.
Robert Bitterman, President and CEO of Phio Pharmaceuticals Corp. (NASDAQ:
$PHIO ), used a Force Family Office webinar to explain how the company's lead candidate, PH-762, works. The drug targets PD-1, a protein that tumors use to switch off the immune system's T cells, by silencing the gene that produces it so those T cells can recognize the tumor and attack it.
Phio Pharmaceuticals Corp. is a B2i Digital Featured Company. See the company's profile at https://b2idigital.com/phio-pharmaceuticals
Bitterman walked through what happens once PH-762 is injected: "...what we do is we're turning off the signal from the gene that's producing the protein, the PD-1. In the absence of PD-1, the T-cells have the ability to basically recover, to reinvigorate, and to go about recognizing the tumor and attack it, which is what a normal healthy immune system will do to a foreign invader."
The webinar also covered:
• PH-762 as a short interfering RNA (siRNA) injected directly into a tumor, part of Phio's INTASYL® platform
• How silencing PD-1 is designed to reinvigorate T cells so they recognize and attack the tumor
• Dr. Mary Spellman's point that treating locally right at the lesion and may mean fewer systemic side effects
• Bitterman's comparison of the approach to shutting off a water faucet at its source
Watch the full presentation: https://youtu.be/QTVd5xDCgGE
Phio Pharmaceuticals is a clinical stage biotechnology company developing immuno oncology therapeutics using its INTASYL® self delivering RNAi platform, led by President and CEO Robert Bitterman. Its lead candidate, PH-762, silences designated genes to make immune cells more effective against cancer cells. Learn more at https://phiopharma.com. For investor information, visit https://phiopharma.com/investors/.
Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com.
Disclosure: B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security.
$EXAS,
$NTRA,
$GH,
$XBI